GSK’s Advair, Serevent Add “Black Box” On Rare Asthma-Related Deaths
Executive Summary
GlaxoSmithKline has revised labeling for Advair and Serevent to include "black box" warnings on an increased risk of asthma-related deaths in patients taking salmeterol
You may also be interested in...
FDA To Conduct Pediatric Safety Analysis for Serevent, Other LABAs
FDA will complete a risk/benefit analysis for pediatric use of GlaxoSmithKline's Serevent (salmeterol) as soon as possible, Pediatric Therapeutics Director Dianne Murphy assured the agency's Pediatrics Advisory Committee Nov. 28
FDA To Conduct Pediatric Safety Analysis for Serevent, Other LABAs
FDA will complete a risk/benefit analysis for pediatric use of GlaxoSmithKline's Serevent (salmeterol) as soon as possible, Pediatric Therapeutics Director Dianne Murphy assured the agency's Pediatrics Advisory Committee Nov. 28
Serevent, Foradil Use With Steroids Should Be Strongly Urged In Labeling
Labeling for GSK's Serevent and Novartis/Schering's Foradil should include a stronger recommendation that the long-acting beta agonist bronchodilators be used concomitantly with inhaled corticosteroids, FDA's Pulmonary-Allergy Drugs Advisory Committee said